Genomics in biopharmaceutical industry

1. Assignment – 02
Seminar on Genomics in
Biopharmaceutical technology
By
Narra Naga Pavan Kumar (KVPY Fellow)
1st
M.Tech Biotech (14IS1D0301)
Institute of Science & Technology, JNTUK University

2. What is Genomics
• study of the complete set of genes of an organism.
• The genome is static.
• Comprises of functional and structural genomics.

3. How in pharmaceutical industry and why
• Goal of Pharma industry : the new drug
• Became Prominent after 1990’ s
• For the new drug targets
• And intellectual property rights
• To reduce the cost wasting at the target validation and identification
•The over all result = Drug Discovery

5. Drug Discovery

6. Why genomics why not the normal
process
• Due to large data available through the genome sequencing projects.
• The amount of free data available through the databases.
• The expressed human genes.
• Many diseases develop as a result of gene networks.
• Led to a new subject called pharmacogenomics.

7. Key Features of pharmacogenomics
• Cause of common fatal diseases.
• Study of individual genotype and its ability to metabolize the foreign
compound.
• Identify the gene or its loci in response to the drug action.
• Diseased could be treated according to the genetic pattern.
• And also by specific markers.
• Medications and dosages for the individual patients.

8. Steps involved in the drug discovery by
genomics

11. Example :HIV Virus RT Enzyme Targeting
Adapted from Edward Arnold (Rutgers University, Piscataway, USA and CABM
• Targeting the RT enzyme of HIV
• Based on the crystal structure of RT Enzyme from HIV Virus two sites are
identified dNTP-binding site, non-nucleoside RT-inhibiting site.
• non-nucleoside RT-inhibiting site is suitable for the disruption of RT Enzyme
activity,
• The most successful candidates, such as TMC120 and TMC125, appear to have
low toxicity (in the micromolar range) and high selectivity.

13. The end